Replaces Prod. #: BML-CA225
Selectively blocks the low threshold (T-type) calcium channel in rat hippocampal CA1 pyramidal neurons. Inhibits Ca2+-influx-induced vasoconstriction of peropheral and cerebral blood vessels with little effect on myogenic activity and Ca2+-depenent myocardial contractility.
Product Details
| Alternative Name: | 1-[bis(4-Fluorophenyl)methyl]-4-(3-phenyl-2-propenyl)piperazine . 2HCl |
| |
| Formula: | C26H26F2N2 . 2HCl |
| |
| MW: | 404.5 . 72.9 |
| |
| CAS: | 30484-77-6 |
| |
| MI: | 14: 4144 |
| |
| Purity: | ≥99% (HPLC) |
| |
| Identity: | Determined by IR. |
| |
| Appearance: | White solid. |
| |
| Solubility: | Soluble in DMSO (25mg/ml), 100% ehanol (5mg/ml) or chloroform:methanol (1:1; 50mg/ml) |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Calcium antagonist effects on low-threshold (T-type) calcium current in rat isolated hippocampal CA1 pyramidal neurons: K. Takahashi & . Akaike; J. Pharmacol. Exp. Ther.
256, 169 (1991),
Abstract;
Calcium antagonism and calcium entry blockade: T. Godfraind et al.; Pharmacol. Rev.
38, 321 (1986),
Abstract;
Platelet-mediated vascular contractions. Inhibition by flunarizine, a calcium-entry blocker: F. De Clerck & J.M. Van Nueten ; Biochem. Pharmacol.
32, 765 (1983),
Abstract;
